Sárosi V - Search Results

1

Survival after surgery following chemotherapy for non-small-cell lung cancer.

Molnár TF, Balikó Z, Sárosi V, Horváth PO. Molnár TF, et al. Among authors: sarosi v. Asian Cardiovasc Thorac Ann. 2010 Feb;18(2):141-6. doi: 10.1177/0218492310361271. Asian Cardiovasc Thorac Ann. 2010. PMID: 20304848

2

[Gemcitabine-cisplatin combination in the first line treatment of non-small cell lung cancer. Our experience and analysis of safety].

Sárosi V, Lénárt T. Sárosi V, et al. Magy Onkol. 2003;47(2):189-93. Epub 2003 Sep 16. Magy Onkol. 2003. PMID: 12975668 Free article. Hungarian.

3

[The role of neoadjuvant therapy in the treatment of locally advanced, stage III non-small-cell lung cancer].

Balikó Z, Sárosi V. Balikó Z, et al. Among authors: sarosi v. Magy Onkol. 2005;49(2):161-8. Epub 2005 Oct 24. Magy Onkol. 2005. PMID: 16249813 Free article. Review. Hungarian.

4

[Erlotinib in second/third line treatment for non-small cell lung cancer (NSCLC)].

Sárosi V, Balikó Z. Sárosi V, et al. Orv Hetil. 2007 Aug 12;148(32):1525-9. doi: 10.1556/OH.2007.28095. Orv Hetil. 2007. PMID: 17675281 Hungarian.

5

[Role of surgery for lung cancer in elderly patients].

Benko I, Horváth OP, Nagy K, Sárosi V, Balikó Z, Potó L, Molnár FT. Benko I, et al. Among authors: sarosi v. Magy Seb. 2008 Feb;61(1):33-7. doi: 10.1556/MaSeb.61.2008.1.7. Magy Seb. 2008. PMID: 18296283 Hungarian.

6

PET-CT imaging and reality.

Baliko Z, Sarosi V, Illes MB, Varga Z, Hegedus G, Molnar P, Szakall S. Baliko Z, et al. Among authors: sarosi v. Pathol Oncol Res. 2011 Jun;17(2):393-5. doi: 10.1007/s12253-010-9299-x. Epub 2010 Sep 17. Pathol Oncol Res. 2011. PMID: 20848252 Free article.

7

[The use of PET/CT in radiotherapy of patients with non-small cell lung cancer].

Lõcsei Z, Hideghéty K, Farkas R, Bellyei S, Sárosi V, Sebestyén K, Sebestyén Z, Kovács P, Mangel L. Lõcsei Z, et al. Among authors: sarosi v. Magy Onkol. 2011 Nov;55(4):274-80. Epub 2011 Jul 4. Magy Onkol. 2011. PMID: 22128310 Free article. Hungarian.

8

[Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma].

Sárosi V, Balikó Z. Sárosi V, et al. Magy Onkol. 2014 Dec;58(4):325-9. Epub 2014 Oct 17. Magy Onkol. 2014. PMID: 25517450 Free article. Hungarian.

9

Bone Metastases and the EGFR and KRAS Mutation Status in Lung Adenocarcinoma--The Results of Three Year Retrospective Analysis.

Bittner N, Balikó Z, Sárosi V, László T, Tóth E, Kásler M, Géczi L. Bittner N, et al. Among authors: sarosi v. Pathol Oncol Res. 2015 Sep;21(4):1217-21. doi: 10.1007/s12253-015-9955-2. Epub 2015 Jun 9. Pathol Oncol Res. 2015. PMID: 26055897 Free article.

10

The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients.

Sárosi V, Balikó Z, Smuk G, László T, Szabó M, Ruzsics I, Mezősi E. Sárosi V, et al. Pathol Oncol Res. 2016 Oct;22(4):755-61. doi: 10.1007/s12253-016-0063-8. Epub 2016 Apr 22. Pathol Oncol Res. 2016. PMID: 27105879 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

43 results

Search Page

Filters